Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE)

X

Xi'an Jiaotong University

Status

Begins enrollment in 4 months

Conditions

Cardiac Tumor

Study type

Observational

Funder types

Other

Identifiers

NCT06100328
XJTU1AF2023LSK-284

Details and patient eligibility

About

This study aims to retrospectively and prospectively collect clinical and biological specimen data from patients with cardiac tumors who meet the inclusion and exclusion criteria. Various techniques, including general molecular biology analysis and multi-omics analysis, will be used to construct a prognostic model for cardiac tumors.

Full description

This study aims to construct a retrospective-prospective long-term follow-up cohort and management system for cardiac tumors through a multi-centre collaborative network. The duration of the study will be divided into retrospective and prospective components. The retrospective study will collect cases of cardiac tumors from 2003-2022; the prospective study is expected to collect cases of cardiac tumors from 2022-2030. The study is expected to assess the disease characteristics, progression patterns, clinical features, natural course and long-term prognosis of cardiac tumors.

Enrollment

40 estimated patients

Sex

All

Ages

3 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who are regularly visited and followed up in the corresponding cardiovascular center.
  • All patients must meet at least one of the following diagnostic criteria for cardiac neoplasms: 1. Cardiac myxoma group; 2. Cardiac fibroma group; 3. Cardiac lipoma group; 4. Cardiac hemangioma group; 5. Cardiac undifferentiated sarcoma; 6. Cardiac angiosarcoma group; 7. Cardiac rhabdomyosarcoma group; 8. Cardiac lymphoma group; 9. Cardiac metastasis group; 10. Other cardiac tumors group.

Exclusion criteria

  • Age <3 years or >80 years old.
  • Pregnant and lactating women.
  • The patient declined to provide informed consent to participate in the study.
  • None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Trial design

40 participants in 5 patient groups

Cardiac myxoma group
Description:
patients who are diagnosed as cardiac myxoma
Cardiac fibroma group
Description:
patients who are diagnosed as cardiac fibroma
Cardiac lipoma group
Description:
patients who are diagnosed as cardiac lipoma
Cardiac hemangioma group
Description:
patients who are diagnosed as cardiac hemangioma
Cardiac malignant tumor group
Description:
patients who are diagnosed as cardiac malignant tumor

Trial contacts and locations

0

Loading...

Central trial contact

Yang Yan; Guoliang Li

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems